Reliance Global vs Health In Tech
EZRA and HIT side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EZRA and HIT compare
Health In Tech is the larger company, worth 17 times as much as Reliance Global ($36.7M against $2.1M).
Health In Tech grew revenue faster over the last twelve months (23.0% versus −21.4% for Reliance Global).
Health In Tech keeps more of each dollar of sales as profit, with a net margin of −12.0% compared with −54.3% at Reliance Global.
Reliance Global scores higher on the StockData Score (4 against 3 for Health In Tech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EZRA | HIT |
|---|---|---|
| Size and price | ||
| Market cap | $2.1M | $36.7M |
| Share price | $2.11 | $0.559 |
| Change, 1 year | −94.2% | −80.8% |
| Change, 5 years | −100.0% | – |
| Beta (5Y) | 1.22 | 1.45 |
| Employees | 40 | 87 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 2 (better) | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 1.1× |
| P/B | 0.3× | – |
| Growth | ||
| Revenue growth (TTM) | −21.4% | 23.0% (better) |
| Revenue growth, 5Y average | 11.2% | – |
| Net income growth (TTM) | – | −390% |
| EPS growth (TTM) | – | −333% |
| Profitability | ||
| Gross margin | – | 53.9% |
| Operating margin | −75.1% | – |
| Net margin | −54.3% | −12.0% (better) |
| Return on equity | −123% | −24.0% (better) |
| Return on invested capital | −60.1% | – |
| Financial health | ||
| Debt / equity | 0.67 | – |
| Current ratio | 1.63 | 2.18 (better) |
| Altman Z-score | −7.32 | 3.84 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 3.7% | 7.1% |
| Held by insiders | 30.2% | 76.6% |
| Insider net buying, 12 months | −$100.0K | −$40.6K (better) |
| Short interest, % of float | 1.1% | 3.9% |
Go deeper
- EZRA stock overview
- EZRA income statement
- EZRA valuation and score
- HIT stock overview
- HIT income statement
- HIT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.